{
    "clinical_study": {
        "@rank": "8163", 
        "arm_group": [
            {
                "arm_group_label": "Normal", 
                "description": "Normal results from clinical exam and free of ocular pathology."
            }, 
            {
                "arm_group_label": "Glaucoma", 
                "description": "Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma."
            }, 
            {
                "arm_group_label": "Retina", 
                "description": "Clinical exam results consistent with retina pathology"
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate clinical substantial equivalence of DRI OCT-1 as comparable to the\n      commercially available Cirrus"
        }, 
        "brief_title": "Clinical Validation of New OCT System", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Normal and Ocular Pathology.", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria for Normal Group\n\n          1. Subjects 18 years of age or older on the date of informed consent\n\n          2. Subjects able to understand the written informed consent and willing to participate\n             as evidenced by signing the informed consent\n\n          3. Subjects presenting at the site with normal eyes (eyes without pathology)\n\n          4. IOP \u2264 21 mmHg bilaterally\n\n          5. BCVA 20/40 or better bilaterally\n\n          6. Both eyes must be free of eye disease\n\n        Exclusion Criteria for Normal Group\n\n          1. Subjects unable to tolerate ophthalmic imaging\n\n          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images\n\n          3. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT\n             'Outside Normal Limits' and/or PSD < 1%\n\n          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on\n             manufacturer's recommendation), defined as fixation losses > 33% or false positives >\n             25%, or false negatives > 25%\n\n          5. Presence of any ocular pathology except for cataract\n\n          6. Previous ocular surgery or laser treatment other than uncomplicated refractive\n             procedure or cataract surgery performed within six months prior to study scanning\n\n          7. Narrow angle\n\n          8. History of leukemia, dementia or multiple sclerosis\n\n          9. Concomitant use of hydroxychloroquine and chloroquine\n\n        Inclusion Criteria for Glaucoma Group\n\n          1. Subjects 18 years of age or older on the date of informed consent\n\n          2. Subjects able to understand the written informed consent and willing to participate\n             as evidenced by signing the informed consent\n\n          3. Subjects presenting at the site with glaucoma\n\n          4. BCVA 20/40 or better in the study eye\n\n          5. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT\n             'Outside Normal Limits' and/or PSD < 1% in the study eye\n\n        Exclusion Criteria for Glaucoma Group\n\n          1. Subjects unable to tolerate ophthalmic imaging\n\n          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images\n\n          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as\n             fixation losses > 33% or false positives > 25%, or false negatives > 25% in the study\n             eye\n\n          4. Presence of any ocular pathology except glaucoma in the study eye\n\n          5. Previous ocular surgery or laser treatment other than uncomplicated procedures\n             performed within six months prior to study scanning in the study eye\n\n          6. History of leukemia, dementia or multiple sclerosis\n\n          7. Concomitant use of hydroxychloroquine and chloroquine\n\n        Inclusion Criteria for Retina Disease Group\n\n          1. Subjects 18 years of age or older on the date of informed consent\n\n          2. Subjects able to understand the written informed consent and willing to participate\n             as evidenced by signing the informed consent\n\n          3. Subjects presenting at the site with retinal disease\n\n          4. IOP <= 21 mmHg in the study eye\n\n          5. BCVA 20/400 or better in the study eye\n\n          6. Diagnosis of some type of retinal pathology by investigator, may include, but not\n             limited to:  Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy,\n             Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others\n\n        Exclusion Criteria for Retinal Disease Group\n\n          1. Subjects unable to tolerate ophthalmic imaging\n\n          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images\n\n          3. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g.,\n             cornea pathology) in the study eye\n\n          4. Previous ocular surgery or laser treatment other than uncomplicated procedures\n             performed within six months prior to study scanning in the study eye\n\n          5. Narrow angle in the study eye\n\n          6. History of leukemia, dementia or multiple sclerosis\n\n          7. Concomitant use of hydroxychloroquine and chloroquine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects that are Normal, or shows signs of Glaucoma or Retinal Ocular Pathology."
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809704", 
            "org_study_id": "DC-03267"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92093"
                    }, 
                    "name": "Hamilton Glaucoma Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jamaica", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11425"
                    }, 
                    "name": "Murray Fingeret"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10022"
                    }, 
                    "name": "Vitreous Retina Macula Consultants of New York"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Topcon DRI OCT-1 Optical Coherence Tomography System for the Acquisition of Retinal Thickness Measurements and Ocular Images of the Posterior Chamber: Agreement and Precision Study", 
        "overall_official": {
            "affiliation": "Director of Clinical Marketing", 
            "last_name": "Michael Sinai, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Retinal Thickness", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809704"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Topcon Medical Systems, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Topcon Medical Systems, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}